학술논문

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Source
In The Lancet Gastroenterology & Hepatology August 2024 9(8):705-717
Subject
Primary Research
Articles
Language
ISSN
2468-1253
Abstract
Funding Ono Pharmaceutical and Bristol Myers Squibb.